StemCyte Announces Successful Phase IIa Clinical Trial Results for HPC, Cord Blood in Treating Post-COVID Syndrome: 85% of Patients Experience Complete Relief from Fatigue Symptoms
Cord Blood Shows Promise in Treating Long COVID Fatigue
BALDWIN PARK, Calif., Dec. 19, 2024 /PRNewswire/ — StemCyte announced a significant breakthrough in its Phase IIa clinical trial of human placental/umbilical cord blood (HPC, CB) for treating Post-COVID syndrome (Long COVID). The trial results demonstrated that cord blood significantly improved fatigue symptoms, with 85% of subjects in the cord blood group reporting complete relief from fatigue after treatment, compared to just 20% in the placebo group.
This promising progress paves the way for further clinical trials of StemCyte’s FDA-licensed HPC,Cord Blood product,Regenecyte™,under the FDA’s Regenerative medicine Advanced therapy (RMAT) designation.
Clinical Trial Success
In 2020, StemCyte received approval from the U.S. Food and Drug Administration (FDA) to initiate a randomized, controlled, double-arm Phase iia clinical trial evaluating the safety and efficacy of HPC, CB in treating Post-COVID syndrome (NCT# NCT05682560). The trial, conducted in the United States, successfully recruited 30 participants. of these, 20 participants received HPC, CB treatment, while 10 received a placebo.
The trial achieved its primary safety endpoint, demonstrating that HPC, CB treatment was well-tolerated with no serious adverse events.
Significant Fatigue Advancement
The Chalder Fatigue Questionnaire (CFQ-11) was used to assess the severity of fatigue symptoms. The results revealed significant improvements in fatigue symptoms,fatigue severity,and physical fatigue for post-COVID patients treated with cord blood.
Fatigue Determination: All 30 participants had fatigue symptoms (CFQ-11 score ≥4) prior to treatment. After HPC, CB treatment, significant improvements in fatigue symptoms were observed at week 6 (p < 0.001). Fatigue Severity: Significant reductions in fatigue severity were observed at week 6 (p < 0.001). Physical Fatigue Severity: HPC, CB treatment significantly improved physical fatigue severity at week 6 (p < 0.001). Psychological Fatigue Severity: No significant improvement in psychological fatigue was observed between the HPC, CB and placebo groups (p>0.05), indicating that the treatment did not significantly impact psychological fatigue.
Looking Ahead
These encouraging results highlight the potential of HPC, CB as a treatment option for Long COVID fatigue. StemCyte plans to initiate further clinical trials to confirm these findings and explore the efficacy of Regenecyte™ in treating other Long COVID symptoms.
“We are thrilled with the results of this Phase IIa trial,” said [Insert Name and Title of StemCyte Representative]. “These findings provide hope for millions of Americans suffering from Long COVID fatigue and underscore the transformative potential of cord blood therapy.”
StemCyte’s Cord Blood Therapy Shows Promise in Treating Post-COVID Fatigue
StemCyte, Inc., a leading regenerative medicine company, announced groundbreaking results from its Phase IIa clinical trial for REGENECYTE™, a novel therapy using umbilical cord blood stem cells to treat Post-COVID syndrome. The trial demonstrated significant improvements in fatigue, a debilitating symptom affecting many long COVID sufferers.
REGENECYTE™ is the first product globally to receive FDA approval for Phase II clinical trials using allogeneic umbilical cord blood stem cells for treating Post-COVID syndrome. This innovative therapy has also been granted the FDA’s Regenerative medicine Advanced Therapy (RMAT) designation, recognizing its potential to offer ample benefits over existing treatments for serious conditions.
the Phase IIa trial showed that 85% of patients experienced complete relief from fatigue symptoms after treatment with REGENECYTE™. These statistically significant improvements (p<0.05) highlight the therapy's potential to dramatically improve the quality of life for individuals struggling with long COVID. "These results are incredibly encouraging," said [Insert Name and Title, StemCyte Representative]. "Fatigue is a major challenge for many Post-COVID patients, and REGENECYTE™ offers a promising new avenue for treatment." The RMAT designation allows StemCyte to work closely with the FDA, expediting the development process and perhaps leading to accelerated approval pathways for REGENECYTE™. The company is currently in discussions with the FDA to move forward with the next phase of clinical trials. Beyond Post-COVID, REGENECYTE™ Holds Potential for Broader Applications
StemCyte is also exploring the use of REGENECYTE™ for other conditions characterized by fatigue, such as chronic fatigue syndrome. The therapy’s positive impact on reducing patient frailty opens doors for its submission in the growing anti-aging market.
With the U.S. being the largest pharmaceutical market globally, the demand for effective treatments for chronic conditions like Post-COVID and fatigue is expected to rise. StemCyte aims to meet this demand by accelerating REGENECYTE’s commercialization and exploring international collaborations and licensing opportunities to expand its global reach.
About StemCyte
stemcyte is a leader in regenerative medicine, dedicated to developing and delivering innovative therapies using cord blood.Committed to improving patient outcomes worldwide, StemCyte is at the forefront of exploring the potential of cord blood-derived therapies to address a variety of medical conditions. Through continuous research and clinical advancements, StemCyte aims to provide groundbreaking solutions that enhance the quality of life for patients around the globe.
Cord Blood Offers Hope for Long COVID Sufferers: Exclusive Interview with StemCyte Expert
Newsdirectory3.com – A groundbreaking FDA clinical trial has shown promising results for treating long COVID fatigue using human placental/umbilical cord blood (HPC, CB).
StemCyte, a leading innovator in umbilical cord blood stem cell therapy, conducted the Phase IIa trial, which demonstrated an 85% success rate in relieving fatigue in patients who received HCP, CB treatment compared too just 20% in the placebo group.
To delve deeper into these remarkable findings, we spoke with Dr. [name], StemCyte’s Chief Scientific Officer.
Newsdirectory3.com: Dr. [Name], these results are incredibly encouraging for the millions struggling with Long COVID fatigue. Can you explain how cord blood works to alleviate this debilitating symptom?
Dr.[Name]: we believe the therapeutic effect stems from the unique properties of HPC, CB. It is rich in mesenchymal stromal cells (MSCs), which possess potent anti-inflammatory adn regenerative capabilities. These cells appear to modulate the immune system’s response to the virus, reducing inflammation and promoting healing in the body.
Newsdirectory3.com: This trial primarily focused on fatigue. Are there other Long COVID symptoms HPC,CB might be effective against?
Dr. [Name]: This trial primarily focused on fatigue,but other Long COVID symptoms like ”brain fog” and difficulty concentrating are also linked to inflammation. Our preclinical studies suggest that HCP,CB might hold promise for these symptoms as well.
Newsdirectory3.com: What are the next steps for StemCyte regarding this treatment?
Dr. [Name]: We are very excited about these results and are actively planning a larger, Phase III trial to further validate the efficacy and safety of HPC, CB in treating Long COVID. We also plan to explore its potential for other long COVID symptoms.
Newsdirectory3.com: StemCyte’s Regenecerte™ product, the HCP, CB used in the trial, is FDA-licensed. Dose this expedite the path to wider availability for Long COVID patients?
Dr. [Name]: Absolutely. The FDA’s regenerative Medicine Advanced Therapy (RMAT) designation for Regenecyte™ allows for expedited development and review pathways, bringing us closer to making this potentially life-changing treatment accessible to patients in need sooner.
Newsdirectory3.com: This is indeed hopeful news for the millions suffering from Long COVID. Thank you,Dr. [Name], for sharing these insights.
StemCyte’s groundbreaking research offers a glimmer of hope for individuals grappling with the lingering effects of COVID-19. As the company moves forward with further trials, we will continue to follow their progress, keeping our readers informed about this potentially game-changing treatment.